•
|
Revenue of $280.4 million increased 7.9% compared with the prior year
|
•
|
Diluted earnings per share was $0.18 compared with diluted loss per share of $4.86 in the prior year; diluted earnings per share from continuing operations, excluding special items, was $0.70, compared to $0.58 in the prior year, a 20.7% increase
|
•
|
Operating income was $40.2 million, compared with operating income of $21.7 million in the prior year; operating income excluding special items was $46.9 million, a 17.1% increase compared with the prior year
|
•
|
Net income attributable to Adtalem was $9.0 million, compared with a net loss of $256.1 million in the prior year, driven by a loss from discontinued operations of $327.6 million; net income from continuing operations attributable to Adtalem, excluding special items, was $35.1 million, a 14.9% increase compared with the prior year
|
•
|
COVID-19 resulted in an estimated revenue loss of approximately $16 million, an operating income loss of approximately $13 million and a loss of earnings per share of approximately $0.20
|
•
|
Revenue of $1,112.4 million increased 5.7% compared with the prior year
|
•
|
Diluted earnings per share was $1.49 compared with diluted loss per share of $1.58 in the prior year; diluted earnings per share from continuing operations, excluding special items, was $2.98, compared to $2.28 in the prior year, a 30.7% increase
|
•
|
Operating income was $161.5 million compared with $142.3 million in the prior year; operating income excluding special items was $202.9 million, a 22.1% increase compared with the prior year
|
•
|
Net income attributable to Adtalem was $76.9 million, compared with a net loss of $85.3 million in the prior year; net income from continuing operations attributable to Adtalem, excluding special items, was $153.7 million, a 24.4% increase compared with the prior year
|
•
|
COVID-19 resulted in an estimated revenue loss of approximately $47 million, an operating income loss of approximately $33 million and a loss of earnings per share of approximately $0.50
|
4Q 2021
|
4Q 2020
|
% Change
| |
Adtalem Global Education Student Enrollments(1) | |||
New students
|
4,974
|
4,757
|
+4.6%
|
Total students
|
40,056
|
38,593
|
+3.8%
|
Chamberlain University
| |||
May Session
| |||
New students
|
4,363
|
4,213
|
+3.6%
|
Total students
|
34,930
|
33,407
|
+4.6%
|
Medical and Veterinary(2) | |||
May Semester
| |||
New students
|
611
|
544
|
+12.3%
|
Total students
|
5,126
|
5,186
|
-1.2%
|
1)
|
Includes the most recently reported enrollment sessions at Adtalem's postsecondary institutions
|
2)
|
Includes enrollments in its medical and veterinary preparatory programs
|
June 30,
| ||||||||
2021
|
2020
| |||||||
Assets:
| ||||||||
Current assets:
| ||||||||
Cash and cash equivalents
|
$
|
494,613
|
$
|
500,516
| ||||
Restricted cash
|
819,003
|
589
| ||||||
Accounts receivable, net
|
67,996
|
87,042
| ||||||
Prepaid expenses and other current assets
|
133,341
|
104,619
| ||||||
Total current assets
|
1,514,953
|
692,766
| ||||||
Noncurrent assets:
| ||||||||
Property and equipment, net
|
297,237
|
286,102
| ||||||
Operating lease assets
|
168,943
|
174,935
| ||||||
Deferred income taxes
|
22,479
|
22,277
| ||||||
Intangible assets, net
|
276,249
|
287,514
| ||||||
Goodwill
|
686,374
|
686,214
| ||||||
Other assets, net
|
87,601
|
78,879
| ||||||
Total noncurrent assets
|
1,538,883
|
1,535,921
| ||||||
Total assets
|
$
|
3,053,836
|
$
|
2,228,687
| ||||
Liabilities and shareholders' equity:
| ||||||||
Current liabilities:
| ||||||||
Accounts payable
|
$
|
56,071
|
$
|
46,484
| ||||
Accrued payroll and benefits
|
64,452
|
48,835
| ||||||
Accrued liabilities
|
129,258
|
104,431
| ||||||
Deferred revenue
|
100,697
|
91,589
| ||||||
Current operating lease liabilities
|
55,329
|
51,644
| ||||||
Current portion of long-term debt
|
3,000
|
3,000
| ||||||
Total current liabilities
|
408,807
|
345,983
| ||||||
Noncurrent liabilities:
| ||||||||
Long-term debt
|
1,067,711
|
286,115
| ||||||
Long-term operating lease liabilities
|
167,855
|
176,032
| ||||||
Deferred income taxes
|
26,991
|
24,975
| ||||||
Other liabilities
|
79,612
|
82,309
| ||||||
Total noncurrent liabilities
|
1,342,169
|
569,431
| ||||||
Total liabilities
|
1,750,976
|
915,414
| ||||||
Commitments and contingencies
| ||||||||
Redeemable noncontrolling interest
|
1,790
|
2,852
| ||||||
Shareholders' equity:
| ||||||||
Common stock, $0.01 par value per share, 200,000 shares authorized; 49,253 and 51,871 shares outstanding as of June 30, 2021 and June 30, 2020, respectively
|
811
|
807
| ||||||
Additional paid-in capital
|
519,826
|
504,434
| ||||||
Retained earnings
|
2,005,105
|
1,927,568
| ||||||
Accumulated other comprehensive loss
|
(7,365
|
)
|
(9,055
|
)
| ||||
Treasury stock, at cost, 31,846 and 28,794 shares as of June 30, 2021 and June 30, 2020, respectively
|
(1,217,307
|
)
|
(1,113,333
|
)
| ||||
Total shareholders' equity
|
1,301,070
|
1,310,421
| ||||||
Total liabilities and shareholders' equity
|
$
|
3,053,836
|
$
|
2,228,687
|
Three Months Ended
|
Year Ended
| |||||||||||||||
June 30,
|
June 30,
| |||||||||||||||
2021
|
2020
|
2021
|
2020
| |||||||||||||
Revenue
|
$
|
280,374
|
$
|
259,729
|
$
|
1,112,380
|
$
|
1,052,001
| ||||||||
Operating cost and expense:
| ||||||||||||||||
Cost of educational services
|
125,635
|
116,050
|
489,233
|
490,054
| ||||||||||||
Student services and administrative expense
|
107,868
|
103,669
|
420,267
|
395,838
| ||||||||||||
Restructuring expense
|
3,199
|
18,289
|
9,804
|
28,628
| ||||||||||||
Business acquisition and integration expense
|
3,432
|
-
|
31,593
|
-
| ||||||||||||
Gain on sale of assets
|
-
|
-
|
-
|
(4,779
|
)
| |||||||||||
Total operating cost and expense
|
240,134
|
238,008
|
950,897
|
909,741
| ||||||||||||
Operating income
|
40,240
|
21,721
|
161,483
|
142,260
| ||||||||||||
Other income (expense):
| ||||||||||||||||
Interest and dividend income
|
961
|
1,013
|
4,094
|
3,688
| ||||||||||||
Interest expense
|
(25,382
|
)
|
(3,925
|
)
|
(41,365
|
)
|
(19,510
|
)
| ||||||||
Investment gain
|
636
|
1,124
|
2,638
|
18
| ||||||||||||
Gain on derivative
|
-
|
26,891
|
-
|
110,723
| ||||||||||||
Net other (expense) income
|
(23,785
|
)
|
25,103
|
(34,633
|
)
|
94,919
| ||||||||||
Income from continuing operations before income taxes
|
16,455
|
46,824
|
126,850
|
237,179
| ||||||||||||
(Provision for) benefit from income taxes
|
(3,594
|
)
|
24,571
|
(25,248
|
)
|
6,358
| ||||||||||
Income from continuing operations
|
12,861
|
71,395
|
101,602
|
243,537
| ||||||||||||
Discontinued operations:
| ||||||||||||||||
Loss from discontinued operations before income taxes
|
(5,839
|
)
|
(57,042
|
)
|
(33,946
|
)
|
(62,578
|
)
| ||||||||
Loss on disposal of discontinued operations before income taxes (includes ($293,360) accumulated other comprehensive income reclassifications for realized loss on foreign currency translation adjustments for the periods ended June 30, 2020)
|
-
|
(287,560
|
)
|
-
|
(287,560
|
)
| ||||||||||
Benefit from income taxes
|
1,915
|
17,045
|
8,819
|
20,823
| ||||||||||||
Loss from discontinued operations
|
(3,924
|
)
|
(327,557
|
)
|
(25,127
|
)
|
(329,315
|
)
| ||||||||
Net income (loss)
|
8,937
|
(256,162
|
)
|
76,475
|
(85,778
|
)
| ||||||||||
Net loss attributable to redeemable noncontrolling interest
|
75
|
110
|
434
|
444
| ||||||||||||
Net income (loss) attributable to Adtalem Global Education
|
$
|
9,012
|
$
|
(256,052
|
)
|
$
|
76,909
|
$
|
(85,334
|
)
| ||||||
Amounts attributable to Adtalem Global Education:
| ||||||||||||||||
Net income from continuing operations
|
$
|
12,936
|
$
|
71,505
|
$
|
102,036
|
$
|
243,981
| ||||||||
Net loss from discontinued operations
|
(3,924
|
)
|
(327,557
|
)
|
(25,127
|
)
|
(329,315
|
)
| ||||||||
Net income (loss) attributable to Adtalem Global Education
|
$
|
9,012
|
$
|
(256,052
|
)
|
$
|
76,909
|
$
|
(85,334
|
)
| ||||||
Earnings (loss) per share attributable to Adtalem Global Education:
| ||||||||||||||||
Basic:
| ||||||||||||||||
Continuing operations
|
$
|
0.26
|
$
|
1.37
|
$
|
1.99
|
$
|
4.55
| ||||||||
Discontinued operations
|
$
|
(0.08
|
)
|
$
|
(6.27
|
)
|
$
|
(0.49
|
)
|
$
|
(6.14
|
)
| ||||
Net
|
$
|
0.18
|
$
|
(4.90
|
)
|
$
|
1.50
|
$
|
(1.59
|
)
| ||||||
Diluted:
| ||||||||||||||||
Continuing operations
|
$
|
0.26
|
$
|
1.36
|
$
|
1.98
|
$
|
4.51
| ||||||||
Discontinued operations
|
$
|
(0.08
|
)
|
$
|
(6.22
|
)
|
$
|
(0.49
|
)
|
$
|
(6.09
|
)
| ||||
Net
|
$
|
0.18
|
$
|
(4.86
|
)
|
$
|
1.49
|
$
|
(1.58
|
)
| ||||||
Weighted-average shares outstanding:
| ||||||||||||||||
Basic shares
|
49,884
|
52,274
|
51,322
|
53,659
| ||||||||||||
Diluted shares
|
50,326
|
52,650
|
51,645
|
54,094
|
(unaudited)
Year Ended June 30,
| ||||||||
2021
|
2020
| |||||||
Operating activities:
| ||||||||
Net income (loss)
|
$
|
76,475
|
$
|
(85,778
|
)
| |||
Loss from discontinued operations
|
25,127
|
329,315
| ||||||
Income from continuing operations
|
101,602
|
243,537
| ||||||
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
| ||||||||
Stock-based compensation expense
|
13,875
|
14,584
| ||||||
Amortization and adjustments to operating lease assets
|
51,380
|
54,716
| ||||||
Depreciation
|
37,598
|
34,428
| ||||||
Amortization of intangible assets
|
10,073
|
10,262
| ||||||
Amortization of debt issuance costs
|
2,657
|
1,566
| ||||||
Impairment of intangible assets
|
1,211
|
-
| ||||||
Reclassification adjustment from other comprehensive income
|
(126
|
)
|
-
| |||||
Provision for bad debts
|
11,573
|
16,152
| ||||||
Deferred income taxes
|
1,519
|
(4,548
|
)
| |||||
Loss on disposals, accelerated depreciation, and adjustments to property and equipment
|
1,912
|
4,564
| ||||||
Realized and unrealized gain on investments
|
(2,638
|
)
|
(18
|
)
| ||||
Realized gain on sale of assets
|
-
|
(4,779
|
)
| |||||
Gain on derivative
|
-
|
(110,723
|
)
| |||||
Changes in assets and liabilities:
| ||||||||
Accounts receivable
|
13,259
|
(12,840
|
)
| |||||
Prepaid expenses and other current assets
|
(18,135
|
)
|
(17,612
|
)
| ||||
Accounts payable
|
8,530
|
(6,340
|
)
| |||||
Accrued payroll and benefits
|
15,646
|
2,173
| ||||||
Accrued liabilities
|
29,740
|
(2,477
|
)
| |||||
Deferred revenue
|
9,108
|
(4,355
|
)
| |||||
Operating lease liabilities
|
(49,880
|
)
|
(53,726
|
)
| ||||
Other assets and liabilities
|
(15,746
|
)
|
(14,999
|
)
| ||||
Net cash provided by operating activities-continuing operations
|
223,158
|
149,565
| ||||||
Net cash used in operating activities-discontinued operations
|
(30,959
|
)
|
(41,873
|
)
| ||||
Net cash provided by operating activities
|
192,199
|
107,692
| ||||||
Investing activities:
| ||||||||
Capital expenditures
|
(48,664
|
)
|
(44,137
|
)
| ||||
Proceeds from sales of marketable securities
|
2,721
|
2,829
| ||||||
Purchases of marketable securities
|
(10,745
|
)
|
(3,015
|
)
| ||||
Proceeds from sale of assets
|
-
|
6,421
| ||||||
Cash received on settlement of derivative
|
-
|
110,723
| ||||||
Cash received on purchase price adjustment
|
-
|
92
| ||||||
Net cash (used in) provided by investing activities-continuing operations
|
(56,688
|
)
|
72,913
| |||||
Net cash used in investing activities-discontinued operations
|
-
|
(3,908
|
)
| |||||
Proceeds from sale of business, net of cash transferred
|
-
|
313,518
| ||||||
Net cash (used in) provided by investing activities
|
(56,688
|
)
|
382,523
| |||||
Financing activities:
| ||||||||
Proceeds from exercise of stock options
|
1,457
|
3,761
| ||||||
Employee taxes paid on withholding shares
|
(4,206
|
)
|
(5,485
|
)
| ||||
Proceeds from stock issued under Colleague Stock Purchase Plan
|
262
|
17
| ||||||
Repurchases of common stock for treasury
|
(100,000
|
)
|
(136,889
|
)
| ||||
Proceeds from long-term debt
|
800,000
|
225,000
| ||||||
Repayments of long-term debt
|
(3,000
|
)
|
(338,000
|
)
| ||||
Payment of debt issuance costs
|
(18,047
|
)
|
-
| |||||
Proceeds from down payment on seller loan
|
-
|
5,200
| ||||||
Payment for purchase of redeemable noncontrolling interest of subsidiary
|
-
|
(6,247
|
)
| |||||
Net cash provided by (used in) financing activities-continuing operations
|
676,466
|
(252,643
|
)
| |||||
Net cash used in financing activities-discontinued operations
|
-
|
(3,466
|
)
| |||||
Net cash provided by (used in) financing activities
|
676,466
|
(256,109
|
)
| |||||
Effect of exchange rate changes on cash, cash equivalents and restricted cash
|
534
|
(33,468
|
)
| |||||
Net increase in cash, cash equivalents and restricted cash
|
812,511
|
200,638
| ||||||
Cash, cash equivalents and restricted cash at beginning of period
|
501,105
|
300,467
| ||||||
Cash, cash equivalents and restricted cash at end of period
|
$
|
1,313,616
|
$
|
501,105
|
Three Months Ended
|
Year Ended
| |||||||||||||||||||||||
June 30,
|
June 30,
| |||||||||||||||||||||||
2021
|
2020
|
Increase (Decrease) |
2021
|
2020
|
Increase (Decrease) | |||||||||||||||||||
Revenue:
| ||||||||||||||||||||||||
Medical and Healthcare
|
$
|
223,466
|
$
|
211,417
|
5.7
|
%
|
$
|
906,901
|
$
|
866,428
|
4.7
|
%
| ||||||||||||
Financial Services
|
56,908
|
48,312
|
17.8
|
%
|
205,479
|
185,573
|
10.7
|
%
| ||||||||||||||||
Total consolidated revenue
|
$
|
280,374
|
$
|
259,729
|
7.9
|
%
|
$
|
1,112,380
|
$
|
1,052,001
|
5.7
|
%
| ||||||||||||
Operating income (loss):
| ||||||||||||||||||||||||
Medical and Healthcare
|
$
|
41,319
|
$
|
39,605
|
4.3
|
%
|
$
|
196,703
|
$
|
166,037
|
18.5
|
%
| ||||||||||||
Financial Services
|
9,392
|
6,762
|
38.9
|
%
|
28,361
|
17,622
|
60.9
|
%
| ||||||||||||||||
Home Office and Other
|
(10,471
|
)
|
(24,646
|
)
|
57.5
|
%
|
(63,581
|
)
|
(41,399
|
)
|
(53.6
|
)%
| ||||||||||||
Total consolidated operating income
|
$
|
40,240
|
$
|
21,721
|
85.3
|
%
|
$
|
161,483
|
$
|
142,260
|
13.5
|
%
|
•
|
Restructuring charges primarily related to real estate consolidations at Adtalem's home office and ACAMS, the write-down of EduPristine's assets, and the sale of Becker's courses for healthcare students.
|
•
|
Business acquisition and integration expense include expenses related to the Walden University acquisition.
|
•
|
Pre-acquisition interest expense related to financing arrangements in connection with the Walden University acquisition.
|
•
|
Gain on the sale of Adtalem's Columbus, Ohio, campus facility.
|
•
|
Gain on the deal-contingent foreign currency hedge arrangement entered into in connection with the sale of Adtalem Brazil completed on April 24, 2020 to economically hedge the Brazilian Real denominated purchase price through mitigation of the currency exchange rate risk.
|
•
|
Tax charges related to the implementation of the Tax Act.
|
•
|
A net tax benefit for a former subsidiary investment loss.
|
•
|
Loss from discontinued operations include the operations of Adtalem Brazil, Carrington, and DeVry University.
|
Three Months Ended
|
Year Ended
| |||||||||||||||||||||||
June 30,
|
June 30,
| |||||||||||||||||||||||
2021
|
2020
|
Increase (Decrease) |
2021
|
2020
|
Increase (Decrease) | |||||||||||||||||||
Medical and Healthcare:
| ||||||||||||||||||||||||
Operating income (GAAP)
|
$
|
41,319
|
$
|
39,605
|
4.3
|
%
|
$
|
196,703
|
$
|
166,037
|
18.5
|
%
| ||||||||||||
Restructuring expense
|
-
|
353
|
-
|
1,707
| ||||||||||||||||||||
Operating income excluding special items (non-GAAP)
|
$
|
41,319
|
$
|
39,958
|
3.4
|
%
|
$
|
196,703
|
$
|
167,744
|
17.3
|
%
| ||||||||||||
Financial Services:
| ||||||||||||||||||||||||
Operating income (GAAP)
|
$
|
9,392
|
$
|
6,762
|
38.9
|
%
|
$
|
28,361
|
$
|
17,622
|
60.9
|
%
| ||||||||||||
Restructuring expense
|
1,629
|
1,726
|
3,044
|
4,842
| ||||||||||||||||||||
Operating income excluding special items (non-GAAP)
|
$
|
11,021
|
$
|
8,488
|
29.8
|
%
|
$
|
31,405
|
$
|
22,464
|
39.8
|
%
| ||||||||||||
Home Office and Other:
| ||||||||||||||||||||||||
Operating loss (GAAP)
|
$
|
(10,471
|
)
|
$
|
(24,646
|
)
|
57.5
|
%
|
$
|
(63,581
|
)
|
$
|
(41,399
|
)
|
(53.6
|
)%
| ||||||||
Restructuring expense
|
1,570
|
16,210
|
6,760
|
22,079
| ||||||||||||||||||||
Business acquisition and integration expense
|
3,432
|
-
|
31,593
|
-
| ||||||||||||||||||||
Gain on sale of assets
|
-
|
-
|
-
|
(4,779
|
)
| |||||||||||||||||||
Operating loss excluding special items (non-GAAP)
|
$
|
(5,469
|
)
|
$
|
(8,436
|
)
|
35.2
|
%
|
$
|
(25,228
|
)
|
$
|
(24,099
|
)
|
(4.7
|
)%
| ||||||||
Adtalem Global Education:
| ||||||||||||||||||||||||
Operating income (GAAP)
|
$
|
40,240
|
$
|
21,721
|
85.3
|
%
|
$
|
161,483
|
$
|
142,260
|
13.5
|
%
| ||||||||||||
Restructuring expense
|
3,199
|
18,289
|
9,804
|
28,628
| ||||||||||||||||||||
Business acquisition and integration expense
|
3,432
|
-
|
31,593
|
-
| ||||||||||||||||||||
Gain on sale of assets
|
-
|
-
|
-
|
(4,779
|
)
| |||||||||||||||||||
Operating income excluding special items (non-GAAP)
|
$
|
46,871
|
$
|
40,010
|
17.1
|
%
|
$
|
202,880
|
$
|
166,109
|
22.1
|
%
|
Three Months Ended
|
Year Ended
| |||||||||||||||
June 30,
|
June 30,
| |||||||||||||||
2021
|
2020
|
2021
|
2020
| |||||||||||||
Net income (loss) attributable to Adtalem (GAAP)
|
$
|
9,012
|
$
|
(256,052
|
)
|
$
|
76,909
|
$
|
(85,334
|
)
| ||||||
Restructuring expense
|
3,199
|
18,289
|
9,804
|
28,628
| ||||||||||||
Business acquisition and integration expense
|
3,432
|
-
|
31,593
|
-
| ||||||||||||
Pre-acquisition interest expense
|
21,750
|
-
|
26,746
|
-
| ||||||||||||
Gain on sale of assets
|
-
|
-
|
-
|
(4,779
|
)
| |||||||||||
Gain on derivative
|
-
|
(26,891
|
)
|
-
|
(110,723
|
)
| ||||||||||
Tax Cuts and Jobs Act of 2017
|
-
|
(2,230
|
)
|
-
|
(2,230
|
)
| ||||||||||
Net tax benefit for a former subsidiary investment loss
|
-
|
(25,688
|
)
|
-
|
(25,688
|
)
| ||||||||||
Income tax impact on non-GAAP adjustments (1)
|
(6,263
|
)
|
(4,483
|
)
|
(16,501
|
)
|
(5,648
|
)
| ||||||||
Loss from discontinued operations
|
3,924
|
327,557
|
25,127
|
329,315
| ||||||||||||
Net income from continuing operations attributable to Adtalem excluding special items (non-GAAP)
|
$
|
35,054
|
$
|
30,502
|
$
|
153,678
|
$
|
123,541
|
Three Months Ended
|
Year Ended
| |||||||||||||||
June 30,
|
June 30,
| |||||||||||||||
2021
|
2020
|
2021
|
2020
| |||||||||||||
Earnings (loss) per share, diluted (GAAP)
|
$
|
0.18
|
$
|
(4.86
|
)
|
$
|
1.49
|
$
|
(1.58
|
)
| ||||||
Effect on diluted earnings per share:
| ||||||||||||||||
Restructuring expense
|
0.06
|
0.35
|
0.19
|
0.53
| ||||||||||||
Business acquisition and integration expense
|
0.07
|
-
|
0.61
|
-
| ||||||||||||
Pre-acquisition interest expense
|
0.43
|
-
|
0.52
|
-
| ||||||||||||
Gain on sale of assets
|
-
|
-
|
-
|
(0.09
|
)
| |||||||||||
Gain on derivative
|
-
|
(0.51
|
)
|
-
|
(2.05
|
)
| ||||||||||
Tax Cuts and Jobs Act of 2017
|
-
|
(0.04
|
)
|
-
|
(0.04
|
)
| ||||||||||
Net tax benefit for a former subsidiary investment loss
|
-
|
(0.49
|
)
|
-
|
(0.47
|
)
| ||||||||||
Income tax impact on non-GAAP adjustments (1)
|
(0.12
|
)
|
(0.09
|
)
|
(0.32
|
)
|
(0.10
|
)
| ||||||||
Loss from discontinued operations
|
0.08
|
6.22
|
0.49
|
6.09
| ||||||||||||
Earnings per share from continuing operations excluding special items, diluted (non-GAAP)
|
$
|
0.70
|
$
|
0.58
|
$
|
2.98
|
$
|
2.28
| ||||||||
Diluted shares used in EPS calculation
|
50,326
|
52,650
|
51,645
|
54,094
|
Three Months Ended |
Twelve Months Ended | |||||||||||||||||||||||||||||||||||||||
FY21 |
FY20 |
FY21 |
FY21 |
FY21 |
FY21 |
FY20 |
FY20 |
FY20 |
FY20 | |||||||||||||||||||||||||||||||
Q4 |
Q4 |
Q4 |
Q3 |
Q2 |
Q1 |
Q4 |
Q3 |
Q2 |
Q1 | |||||||||||||||||||||||||||||||
Net cash provided by operating activities-continuing operations (GAAP)
|
$
|
55,953
|
$
|
57,535
|
$
|
223,158
|
$
|
224,740
|
$
|
259,091
|
$
|
200,743
|
$
|
149,565
|
$
|
170,304
|
$
|
159,150
|
$
|
165,413
| ||||||||||||||||||||
Capital expenditures
|
(13,820
|
)
|
(12,203
|
)
|
(48,664
|
)
|
(47,047
|
)
|
(48,001
|
)
|
(48,144
|
)
|
(44,137
|
)
|
(44,239
|
)
|
(45,827
|
)
|
(54,689
|
)
| ||||||||||||||||||||
Free cash flow (non-GAAP)
|
$
|
42,133
|
$
|
45,332
|
$
|
174,494
|
$
|
177,693
|
$
|
211,090
|
$
|
152,599
|
$
|
105,428
|
$
|
126,065
|
$
|
113,323
|
$
|
110,724
|
Year Ended
| ||||
June 30, 2021
| ||||
Expected earnings per share, diluted (GAAP)
|
$2.73 to 2.98
| |||
Expected effects on diluted earnings per share:
| ||||
Estimated incremental acquisition integration costs
|
0.52
| |||
Estimated incremental purchase accounting adjustment - deferred revenue
|
0.18
| |||
Estimated incremental purchase accounting adjustment - intangible amortization
|
1.26
| |||
Estimated income tax impact on non-GAAP adjustments(1)
|
(0.49
|
)
| ||
Expected adjusted earnings per share from continuing operations excluding special items, diluted (non-GAAP)(2)
|
$4.20 to 4.45
| |||
Diluted shares used in EPS calculation
|
50.1
|
Year Ended
| ||||
June 30, 2021
| ||||
Expected revenue (GAAP)
|
$1,676 to 1,726
| |||
Estimated incremental purchase accounting adjustment - deferred revenue
|
9
| |||
Expected revenue excluding special items (non-GAAP)(3)
|
$1,685 to 1,735
|
Attachments
- Original document
- Permalink
Disclaimer
Adtalem Global Education Inc. published this content on 19 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 19 August 2021 20:13:11 UTC.